Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients

INTRODUCTION: In immunocompromised patients, SARS-CoV-2 mRNA vaccine has been used in Italy from the beginning of the vaccination campaign, but several studies have shown that the serological response of onco-hematological patients was reduced compared to healthy subjects, due to the state of immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Pascale, Sara Pasquina, Nuccorini, Roberta, Pierri, Teresa, Di Mare, Roberta, Fabio, Lucia, Lerose, Emilia, Merlino, Maria Antonietta, Schiavo, Pietro, Amendola, Angela, Brucoli, Gino, Caputo, Maria Denise, Chitarrelli, Ida, Cimminiello, Michele, Coluzzi, Sabrina, Filardi, Nunzio Biagio, Matturro, Angela, Vertone, Domenico, Poggiaspalla, Monica, Malaspina, Francesco, Musuraca, Gerardo, Coralluzzo, Gennaro, Mannarella, Clara, Musto, Clelia, Bellettieri, Angela Pia, Martinelli, Giovanni, Cerchione, Claudio, Pizzuti, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393554/
https://www.ncbi.nlm.nih.gov/pubmed/36003404
http://dx.doi.org/10.3389/fimmu.2022.892331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393554/
https://www.ncbi.nlm.nih.gov/pubmed/36003404
http://dx.doi.org/10.3389/fimmu.2022.892331

Ejemplares similares